Seres Therapeutics to Present at the Stifel 2018 Healthcare Conference
November 09 2018 - 7:00AM
Business Wire
Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it
will present at the Stifel 2018 Healthcare Conference in New York,
NY on Tuesday, November 13th at 9:30 a.m. ET.
A live audio webcast of the presentation will be available under
the “Investors and Media” section of Seres’ website. A replay will
become available approximately one hour after the event and will be
archived for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. (NASDAQ:MCRB) is a leading microbiome
therapeutics platform company developing a novel class of
biological drugs that are designed to treat disease by restoring
the function of a dysbiotic microbiome, where the state of
bacterial diversity and function is imbalanced. Seres’ lead
program, SER-109, has obtained Breakthrough Therapy and Orphan Drug
designations from the U.S. Food and Drug Administration and is in
Phase 3 development for multiply recurrent C. difficile infection.
SER-287 has successfully completed a Phase 1b study in patients
with mild-to-moderate ulcerative colitis. Seres is developing
SER-262, the first ever synthetic microbiome therapeutic candidate,
in a Phase 1b study in patients with primary C. difficile
infection. Seres is also advancing SER-401 to augment the efficacy
of immuno-oncology treatment. For more information, please visit
www.serestherapeutics.com. Follow us on Twitter @SeresTx.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181109005022/en/
Seres TherapeuticsCarlo Tanzi, Ph.D., 617-203-3467Vice
President, Investor Relations and Corporate
Communicationsctanzi@serestherapeutics.com
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Apr 2023 to Apr 2024